ANGO - Lackluster Growth And Margins Remain Major Issues For AngioDynamics

• Declines in procedure counts have increased the pressures on AngioDynamics' business, but weak core growth is a long-standing issue, as is weak margin leverage.
• Growth drivers like AngioVac, Auryon, and NanoKnife (further down the road), could still ultimately drive better revenue growth, but investors have been waiting a very long time for sustained growth.
• Valuation is very undemanding, but it's hard to see this stock working without a line of sight to better, sustainable revenue growth and/or double-digit EBITDA margins.

For further details see: